奥希替尼半衰期有多长？深入解析药物代谢与用药间隔的科学依据

In November 2015, a prescription drug targeting epidermal growth factor receptor (EGFR) gene mutations (especially the T790M mutation) received accelerated approval from the U.S. Food and Drug Administration (FDA) for the first time. It should be used only as directed by a doctor.

Lorlatinib is a third-generation drug for the treatment of non-small cell lung cancer (NSCLC). It has strong inhibitory effects on dual receptor tyrosine kinase (RTK) of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1). It is used to treat patients who have previously received at least one ALK inhibitor, such as the first-generation ALK inhibitor crizotinib.

Cabozantinib was approved by the FDA on November 29, 2012, for the treatment of progressive, metastatic medullary thyroid carcinoma; for the treatment of advanced renal cell carcinoma; and for second-line treatment of advanced hepatocellular carcinoma. Cabozantinib is a multi-receptor tyrosine kinase inhibitor. It inhibits the activity of RET, hepatocyte growth factor receptor, angiogenic factor receptor 1 (VEGFR-1, VEGFR-2, VEGFR-3), stem cell growth factor receptor (KIT), tyrosine kinase receptor (TRKB), FMS-like tyrosine kinase 3 (FLT-3), AXL, and epidermal growth factor-like domain tyrosine kinase 2 (TIE-2). These kinase receptors...

Lorlatinib is a third-generation drug for the treatment of non-small cell lung cancer (NSCLC). It exhibits strong inhibitory activity against both anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) receptor tyrosine kinase (RTK). It is used to treat patients who have previously received at least one ALK inhibitor, such as the first-generation ALK inhibitor crizotinib or the second-generation ALK inhibitor crizotinib...

Multiple clinical trials have demonstrated that dacomitinib has the potential to prolong progression-free survival (PFS) and overall survival (OS) compared to other EGFR-TKIs. For example, in the ARCHER-1050 clinical study, the median PFS and OS in the dacomitinib group were significantly better than those in the gefitinib group.

Ceritinib inhibits the activity of ALK protein, thereby suppressing cells expressing ALK fusion proteins (such as EML4-ALK and NPM-ALK) to achieve a therapeutic effect in cancer treatment and, to some extent, overcomes patients' resistance to first-generation ALK inhibitors.